599
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma

, , , , , , , , , , ORCID Icon, & show all
Pages 29-38 | Received 14 Apr 2019, Accepted 04 Nov 2019, Published online: 18 Nov 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Anna Korycka-Wołowiec, Dariusz Wołowiec & Tadeusz Robak. (2020) The safety of available chemo-free treatments for mantle cell lymphoma. Expert Opinion on Drug Safety 19:11, pages 1377-1393.
Read now

Articles from other publishers (2)

Sining Zhu, Samantha Gokhale, Jaeyong Jung, Eris Spirollari, Jemmie Tsai, Johann Arceo, Ben Wang Wu, Eton Victor & Ping Xie. (2021) Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets – Beyond B Lymphocytes. Frontiers in Cell and Developmental Biology 9.
Crossref
Vincent Sibaud, Marie Beylot-Barry, Caroline Protin, Emmanuelle Vigarios, Christian Recher & Loic Ysebaert. (2020) Dermatological Toxicities of Bruton’s Tyrosine Kinase Inhibitors. American Journal of Clinical Dermatology 21:6, pages 799-812.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.